Closing the Care Gap

Autonomous AI can improve access to eye exams and follow up care for people living with diabetes

Close the care gap: Bring the exam to the patient

LumineticsCore™

Digital Diagnostics created the first ever FDA De Novo cleared fully autonomous AI system for the detection of diabetic retinopathy.

Validated for use in a frontline care setting	Diagnostic results at point-of-care
No need for specialist overread or telemedicine call backs	Simple user interface
Reimbursable with CPT® Code 92229	Closes HEDIS care gap

Seamlessly integrates into clinical workflows

► Operated by existing clinic staff
► Fully integrated with EHRs

How LumineticsCore Works

Image capture (eyes) → **Diagnostic evaluation** → **Results and triage at the point-of-care**

As part of a patient's diabetes care, a trained operator captures two images per eye

LumineticsCore's software diagnoses the patient. Results are sent directly to the EHR

A PDF report with easy to read results is produced and the patient is referred to a specialist as needed

NEGATIVE for more than mild DR, recheck in 1 year

POSITIVE for more than mild DR, refer to eye care

DIGITAL DIAGNOSTICS
AI the right way.®

Closing the Care Gap

Autonomous AI can improve access to eye exams and follow up care for people living with diabetes

LumienticsCore is reimbursable using category 1 CPT® Code 92229

CPT® Code 92229 is considered a diagnostic service, which facilitates billing of LumineticsCore for the detection of diabetic retinopathy, a leading causes of blindness.

The American Medical Association (AMA) highlighted the potential of the additional code for improving access to high quality care for underserved populations.[1]

HEDIS recognizes AI for closing the care gap

The National Committee for Quality Assurance (NCQA) has updated the HEDIS quality measure to clarify that AI systems close the care gap.

LumineticsCore is invariant to racial and other biases[2]

LumineticsCore makes decisions with the same clinical reasoning as a doctor, using biomarker-based AI to evaluate for hemorrhages, microaneurysms exudates, and new vessels.

> "LumineticsCore really is cutting edge technology that helps me market to patients, prevent vision loss from diabetes, and improve my quality scores."
>
> - Lee Herman, MD, FACP Johns Creek Primary Care

1. American Medical Association (2020). AMA releases 2021 CPT code set. Accessed September 8, 2020.
https://www.ama-assn.org/press-center/press-releases/ama-releases-2021-cpt-code-set
2. Abramoff MD, Tobey D, Char DS. Lessons learnt about Autonomous AI: Finding a safe, efficacious and ethical path through the development process. Am J Ophthalmol. 2020.